2024年12月6日 · Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates

Athira is currently conducting a first-in-human, dose escalation Phase 1 clinical trial evaluating safety, tolerability and pharmacokinetics of ATH-1105 in up to 80 healthy volunteers. Athira …

At Athira, we are committed to restoring, rebuilding and retaining connections. Our scientific philosophy is rooted in supporting a healthy neuronal network, improving the lives of patients …

2024年10月22日 · Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS)

At Athira, We Are Focused on Improving Neuronal Health by Promoting Natural Repair Systems. Neurodegenerative diseases — like Alzheimer’s and Parkinson’s — occur when the brain is …

Select Athira Scientific Publications By clicking on the links below, you will access PDF reprints of peer-reviewed publications made available by scientific journals via open-access. …

Athira is committed to building, restoring and maintaining connections. Our science is based on the repair of neuronal connections and our philosophy is based on the maintenance of …

2024年1月3日 · Athira aims to alter the course of neurological disease by advancing its pipeline of therapeutic candidates targeting the neurotrophic HGF system for Alzheimer’s and Parkinson’s …

• Charles Bernick is a principal investigator on Athira clinical studies and is a clinical professor at University of Washington, Department of Neurology • Sam Dickson and Suzanne Hendrix are …

BOTHELL, Wash., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to …